Recent Study: Kazakhstan Pharmaceuticals & Healthcare Report Q1 2015

From: Fast Market Research, Inc.
Published: Wed Dec 31 2014

Plans to boost government spending on healthcare will be positive for the pharmaceutical industry as well as other participants in the healthcare sector. Over the longer term, the introduction of compulsory health insurance will create a large pool of funding for further growth. However, a key risk to our outlook is oil prices and their effect on Kazakh government revenues.

Headline Expenditure Projections

* Pharmaceuticals: KZT273.92bn (USD1.80bn) in 2013 to KZT335.18bn (USD1.84bn) in 2014; +22.4% in local currency terms and 2.3% in US dollar terms.
* Healthcare: KZT1,487.03bn (USD9.77bn) in 2013 to KZT1,775.11bn (USD9.75bn) in 2014; +19.4% in local currency terms and -0.2% in US dollar terms.

Full Report Details at

Risk/Reward Index

Kazakhstan has a RRI score of 49.7 out of 100, making it the 13th most attractive pharmaceutical market in Emerging Europe. Although the Kazakh market is characterised by relatively few market barriers and rapid growth, the industry's potential rewards are moderated by low per capita spending and an unfavourable rural-urban population split.

Key Trends And Developments


* Kazakhstan's President Nursultan Nazarbayev has asked for the establishment of a compulsory health insurance fund in the country. Nazarbayev said: 'In 2017 we will need to reorganise the Committee of Public Medical Services into a Ministry of Health and Social Development and to create a mandatory health insurance fund.' The new health insurance fund will be based on the existing single healthcare system in the country, according to Nazarbayev. A reform bill in lieu of the fund is expected to be developed by 2016.
* Kazakhstan's Ministry of Investment and Development organised a meeting with representatives of 14 countries to discuss investment opportunities in the field of health and medicine in the country. Around 23 pharmaceutical companies have showed interest in spending in the country's healthcare and medicine with a possibility of localisation of their...

The Kazakhstan Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Kazakhstan Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Kazakhstani pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Kazakhstan to test other views - a key input for successful budgeting and strategic business planning in the Kazakhstani pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Peru Pharmaceuticals & Healthcare Report Q1 2015
- Lebanon Pharmaceuticals & Healthcare Report Q1 2015
- Turkey Pharmaceuticals & Healthcare Report Q1 2015
- India Pharmaceuticals & Healthcare Report Q1 2015
- Slovenia Pharmaceuticals & Healthcare Report Q1 2015
Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email:
Contact Phone: 1-413-485-7001

Visit website »